J&J's MD&D Segment Plans More Than 30 Major Product Filings Through 2016

(RTTNews) - Johnson & Johnson (JNJ) said that its Medical Devices and Diagnostics or MD&D businesses are positioned for continued growth with many recently launched products and a pipeline of more than 30 major product filings planned by the end of 2016.

The company said that the meaningful innovation is intended to help health care systems, governments and providers improve clinical outcomes, increase patient satisfaction and contain costs; three tenets shared by most global health care reform acts, known widely as the Triple Aim.

The MD&D segment invested nearly $1.8 billion in research and development in 2013 to expand its global leadership position.

Johnson & Johnson noted that at a meeting today with members of the investment community, senior leaders from its Medical Devices and Diagnostics segment will outline plans to improve patient outcomes and expand their market leadership through innovative products, new business models and a significant focus on fast-growing emerging markets.

The company stated that its MD&D businesses compete in approximately 30 percent of the estimated $370 billion global market, and many of the key markets in which these businesses compete are projected to grow faster than the overall market over the next 5 years.